Results 61 to 70 of about 115,987 (377)

Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review

International Journal of Molecular Sciences, 2019
Diabetes is a chronic metabolic disorder which leads to high blood sugar levels over a prolonged period. Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and results from the body’s ineffective use of insulin.
Rui Liu, Jianming Cheng, Hao Wu
semanticscholar   +1 more source

Dipeptidyl peptidase 3 modulates the renin–angiotensin system in mice

Journal of Biological Chemistry, 2020
Dipeptidyl peptidase 3 (DPP3) is a zinc-dependent hydrolase involved in degrading oligopeptides with 4–12 amino acid residues. It has been associated with several pathophysiological processes, including blood pressure regulation, pain signaling, and ...
Shalinee Jha, Ulrike Taschler, O. Domenig, M. Poglitsch, Benjamin Bourgeois, M. Pollheimer, Lisa M. Pusch, Grazia Malovan, S. Frank, T. Madl, K. Gruber, R. Zimmermann, P. Macheroux   +12 more
semanticscholar   +1 more source

The role of Dipeptidyl Peptidase‐4 in cutaneous disease

Experimental Dermatology, 2020
Dipeptidyl peptidase‐4 (DPP4) is a multifunctional, transmembrane glycoprotein present on the cell surface of various tissues. It is present in multiple molecular forms including cell surface and soluble.
P. Patel, V. A. Jones, K. Kridin, K. Amber   +3 more
semanticscholar   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Overview of molecular signatures of senescence and associated resources: pros and cons

FEBS Open Bio, EarlyView.
Cells can enter a stress response state termed cellular senescence that is involved in various diseases and aging. Detecting these cells is challenging due to the lack of universal biomarkers. This review presents the current state of senescence identification, from biomarkers to molecular signatures, compares tools and approaches, and highlights ...
Orestis A. Ntintas, Sylvia Vagena, Pavlos Pantelis, Giorgos Theocharous, Russel Petty, Konstantinos Evangelou, Vassilis G. Gorgoulis   +6 more
wiley   +1 more source

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study [PDF]

, 2018
Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter
Avogaro Angelo, Baldi, Ileana, Bossi, Antonio Carlo, Bottigliengo, Daniele, Cavalot, Franco, D'Angelo, Federica, DARWIN-T2D Network, Fadini, Gian Paolo, Morano S., Raffaella Buzzetti, Zatti, Giancarlo   +10 more
core   +1 more source

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats

Journal of Pharmacological Sciences, 2004
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-
Kotaro Takasaki, Takao Nakajima, Kimihisa Ueno, Yuji Nomoto, Katsuya Higo   +4 more
doaj   +1 more source

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Randomized controlled trials showed that newer glucose‐lowering agents are cardioprotective, but most participants were men. It is unknown whether benefits are similar in women.
Valeria Raparelli, Malik Elharram, Cristiano S. Moura, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli, Louise Pilote   +6 more
doaj   +1 more source

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]

, 2018
Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel, Buzzetti, Raffaella, Chevalier, Soazig, Lavalle-Gonzalez, Fernando, Merino-Trigo, Ana, Pettus, Jeremy Hodson, Stella, Peter, Yale, Jean-François   +7 more
core   +4 more sources

Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells

FEBS Open Bio, EarlyView.
Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi, Zainab Quraishi, Shima Khezri Azizi Far, Madaleine Ward, Aidan Conway, Reem Abdulredha, Eman Mshari, Yousif A. Shamsaldeen   +7 more
wiley   +1 more source